loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Ubrogepant

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Ubrogepant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AbbVie's Ubrelvy To Lead $16B+ Migraine Market By 2033 In Major Pharma Nations
    AbbVie's Ubrelvy To Lead $16B+ Migraine Market By 2033 In Major Pharma Nations

    11 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/abbvies-ubrelvy-be-top-migraine-seller-2033-total-market-hit-16b-plus-across-biggest

    FIERCE PHARMA
    11 Sep 2024
    Share Share
    AbbVie's Ubrelvy Effective Against Early Migraine Signs: Study
    AbbVie's Ubrelvy Effective Against Early Migraine Signs: Study

    30 Aug 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/study-abbvies-ubrelvy-excels-preventative-migraine-headaches

    FIERCE PHARMA
    30 Aug 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Ubrogepant Tablets
    FDA Confirms Paragraph IV Patent Litigation for Ubrogepant Tablets

    27 Feb 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ubrogepant-tablets-56703.pdf

    FDA
    27 Feb 2024
    Share Share
    AbbVie's Ubrelvy significantly cuts headache pain if taken during prodrome
    AbbVie's Ubrelvy significantly cuts headache pain if taken during prodrome

    17 Nov 2023

    // PRESS RELEASE

    https://news.abbvie.com/news/press-releases/results-published-in-lancet-show-ubrelvy-ubrogepant-reduces-headache-phase-migraine-attack-when-dosed-during-prodrome-migraine.htm

    PRESS RELEASE
    17 Nov 2023
    Share Share
    AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY®
    AbbVie Announces Serena Williams as Spokesperson to Shed Light on UBRELVY®

    04 Aug 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/abbvie-announces-serena-williams-as-spokesperson-to-shed-light-on-ubrelvy-ubrogepant-as-an-effective-treatment-option-for-migraine-attacks-301106556.html

    PRNEWSWIRE
    04 Aug 2020
    Share Share
    With DEA scheduling, Lilly's Reyvow cleared for launch
    With DEA scheduling, Lilly's Reyvow cleared for launch

    31 Jan 2020

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/lilly-set-for-first-2020-launch-after-dea-scheduling-for-migraine-drug-reyvow

    Eric Sagonowsky FIERCE PHARMA
    31 Jan 2020
    Share Share